Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
NEPHROLOGY / CLINICAL RESEARCH
Association between immune cells and membranous nephropathy: a two-sample Mendelian randomization study
1
Research Centre of Basic Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
2
Zhongshan School of Medicine, Sun Yat-sen University, Ministry of Education, Guangzhou, China
3
Department of Nephrology, Hangzhou Ninth People’s Hospital, Hangzhou, China
These authors had equal contribution to this work
Submission date: 2024-07-15
Final revision date: 2024-10-02
Acceptance date: 2024-10-19
Online publication date: 2024-10-26
Corresponding author
Congyan Hou
Research Centre of Basic Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
Research Centre of Basic Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
Article (PDF)
Supplementary files
References (37)
Association between immune - Supplemetary Table SII.XLSX
Association between immune - Supplemetary Table SIII.XLSX
Association between immune - Supplemetary Table SIV.XLSX
Association between immune - Supplemetary Table SV.XLSX
Association between immune - Supplemetary Table SVI.XLSX
Association between immune - Supplemetary Table SVII.XLSX
Association between immune - Supplemetary Table SI.XLSX
Association between immune - Supplemetary Table SVIII.XLSX
KEYWORDS
membranous nephropathyimmune cellsMendelian randomizationsingle nucleotide polymorphismgenome-wide association studies
TOPICS
ABSTRACT
Introduction:
Multiple studies have indicated that immune cells play a significant role in the occurrence and development of membranous nephropathy (MN). However, the causal relationship between the two has not been fully established. To further investigate this, we employed a Mendelian randomization (MR) study design.
Material and methods:
Genetic instrumental variables for immune cells were sourced from an extensive genome-wide association study (GWAS). MN summary statistics, involving 2,150 cases and 5,829 controls, were obtained from a separate GWAS. The primary analysis employed the inverse-variance weighted (IVW) method. To explore reverse causation, a reverse MR analysis was undertaken. Rigorous sensitivity analyses were conducted to ensure the resilience and reliability of the study’s findings.
Results:
We identified eight immunophenotypes associated with a reduced risk of MN, and all of them were protective factors for MN. The sensitivity analyses consistently yielded similar results for these immune traits. In the reverse MR analysis, we did not observe any statistically significant associations between MN and these eight immunophenotypes.
Conclusions:
Our study, utilizing genetic approaches, provides evidence for a causal relationship between immune cells and MN, which has implications for clinical diagnosis and treatment. Further comprehensive investigations are needed to explore the detailed mechanisms underlying the impact of immune cells on MN.
Multiple studies have indicated that immune cells play a significant role in the occurrence and development of membranous nephropathy (MN). However, the causal relationship between the two has not been fully established. To further investigate this, we employed a Mendelian randomization (MR) study design.
Material and methods:
Genetic instrumental variables for immune cells were sourced from an extensive genome-wide association study (GWAS). MN summary statistics, involving 2,150 cases and 5,829 controls, were obtained from a separate GWAS. The primary analysis employed the inverse-variance weighted (IVW) method. To explore reverse causation, a reverse MR analysis was undertaken. Rigorous sensitivity analyses were conducted to ensure the resilience and reliability of the study’s findings.
Results:
We identified eight immunophenotypes associated with a reduced risk of MN, and all of them were protective factors for MN. The sensitivity analyses consistently yielded similar results for these immune traits. In the reverse MR analysis, we did not observe any statistically significant associations between MN and these eight immunophenotypes.
Conclusions:
Our study, utilizing genetic approaches, provides evidence for a causal relationship between immune cells and MN, which has implications for clinical diagnosis and treatment. Further comprehensive investigations are needed to explore the detailed mechanisms underlying the impact of immune cells on MN.
REFERENCES (37)
1.
Hua MR, Zhao YL, Yang JZ, et al. Membranous nephropathy: mechanistic insights and therapeutic perspectives. Int Immunopharmacol 2023; 120: 110317.
2.
Wu L, Lai J, Ling Y, et al. A review of the current practice of diagnosis and treatment of idiopathic membranous nephropathy in China. Med Sci Monit 2021; 27: e930097.
3.
Wang YN, Feng HY, Nie X, et al. Recent advances in clinical diagnosis and pharmacotherapy options of membranous nephropathy. Front Pharmacol 2022; 13: 907108.
4.
Dantas M, Silva LBB, Pontes BTM, et al. Membranous nephropathy. J Bras Nefrol 2023; 45: 229-43.
5.
Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J 2019; 95: 23-31.
6.
Ma DH, Yang XD, Hua QJ, et al. Changes and significance of Treg and Th17 in adult patients with primary membranous nephropathy. Clin Nephrol 2021; 96: 155-64.
7.
Cantarelli C, Jarque M, Angeletti A, et al. A comprehensive phenotypic and functional immune analysis unravels circulating anti-phospholipase A2 receptor antibody secreting cells in membranous nephropathy patients. Kidney Int Rep 2020; 5: 1764-76.
8.
Caravaca-Fontan F, Fernandez-Juarez GM, Floege J, et al. The management of membranous nephropathy-an update. Nephrol Dial Transplant 2022; 37: 1033-42.
9.
Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381: 36-46.
10.
Li Y, Liu H, Yan H, Xiong J. Research advances on targeted-Treg therapies on immune-mediated kidney diseases. Autoimmun Rev 2023; 22: 103257.
11.
Sekula P, Del Greco MF, Pattaro C, Kottgen A. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol 2016; 27: 3253-65.
12.
Evans DM, Smith GD. Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet 2015; 16: 327-50.
13.
Kumagai T, Ota T, Tamura Y, et al. Time to target uric acid to retard CKD progression. Clin Exp Nephrol 2017; 21: 182-92.
14.
Orru V, Steri M, Sidore C, et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet 2020; 52: 1036-45.
15.
Xie J, Liu L, Mladkova N, et al. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat Commun 2020; 11: 1600.
16.
Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018; 362: k601.
17.
Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA 2017; 318: 1925-26.
18.
Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018; 7: e34408.
19.
Shim H, Chasman DI, Smith JD, et al. A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. PLoS One 2015; 10, e0120758.
20.
Burgess S, Thompson SG, CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol 2011; 40: 755-64.
21.
Bowden J, Smith GD, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44: 512-25.
22.
Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018; 50: 693-8.
23.
Bowden J, del Greco MF, Minelli C, et al. Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption. Int J Epidemiol 2019; 48: 728-42.
24.
Alikhan MA, Huynh M, Kitching AR, Ooi JD. Regulatory T cells in renal disease. Clin Transl Immunology 2018; 7: e1004.
25.
Motavalli R, Etemadi J, Soltani-Zangbar MS, et al. Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy. Cytokine 2021; 141: 155452.
26.
Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 2008; 105: 10113-8.
27.
Timperi E, Barnaba V. CD39 regulation and functions in T cells. Int J Mol Sci 2021; 22: 8068.
28.
Wang YM, McRae JL, Robson SC, et al. Regulatory T cells participate in CD39-mediated protection from renal injury. Eur J Immunol 2012; 42: 2441-51.
29.
Beyersdorf N, Kerkau T, Hunig T. CD28 co-stimulation in T-cell homeostasis: a recent perspective. Immunotargets Ther 2015; 4: 111-22.
30.
Liu Y, Liu YE, Tong CC, et al. CD28 deficiency attenuates primary blast-induced renal injury in mice via the PI3K/Akt signalling pathway. BMJ Mil Health 2020; 166: e66-9.
31.
Nitta K, Horita S, Ogawa S, et al. Resistance of CD28-deficient mice to autologous phase of anti-glomerular basement membrane glomerulonephritis. Clin Exp Nephrol 2003; 7: 104-12.
32.
Schamel WW, Alarcon B, Minguet S. The TCR is an allosterically regulated macromolecular machinery changing its conformation while working. Immunol Rev 2019; 291: 8-25.
33.
Xiong J, Qiao Y, Yu Z, et al. T-lymphocyte subsets alteration, infection and renal outcome in advanced chronic kidney disease. Front Med (Lausanne) 2021; 8: 742419.
34.
Liao W, Zheng H, Wu S, et al. The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis. Am J Nephrol 2017; 46: 371-9.
35.
Sung SJ, Ge Y, Dai C, et al. Dependence of glomerulonephritis induction on novel intraglomerular alternatively activated bone marrow-derived macrophages and Mac-1 and PD-L1 in lupus-prone NZM2328 mice. J Immunol 2017; 198: 2589-601.
36.
Robson KJ, Ooi JD, Holdsworth SR, Rossjohn J, Kitching AR. HLA and kidney disease: from associations to mechanisms. Nat Rev Nephrol 2018; 14: 636-55.
37.
Ooi JD, Petersen J, Tan YH, et al. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 2017; 545: 243-7.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
